48-wk Open Label Phase IIIb to Evaluate Efficacy and Safety
Status:
Completed
Trial end date:
2004-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy and safety of rosuvastatin in reducing
low density lipoprotein cholesterol levels to internationally recognised goals in subjects
with dyslipidaemia.